3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
5
Phase 3
3
Phase 1
2
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Mature B-cell Neoplasms
1
Hematologic Neoplasms
1
Interventions
Specimen Handling
146
pembrolizumab
118
Magnetic Resonance Spectroscopy
117
Cyclophosphamide
113
Biopsy
96
fludarabine
88
Nivolumab
52
Carboplatin
51
Cisplatin
47
Gemcitabine
46
Radiotherapy
41
venetoclax
40
Cetuximab
40
fludarabine phosphate
39
Paclitaxel
39
Ipilimumab
34
atezolizumab
33
Fluorouracil
33
Bevacizumab
32
Oxaliplatin
27
Leucovorin
27
Dexamethasone
26
durvalumab
25
X-Rays
25
Irinotecan
25
Radiation
24
Cytarabine
23
Azacitidine
23
Injections
22
Temozolomide
20
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1
×
ARQ531
×
90 days
×
Clear all
NCT05673460
2026-05-13
MK-1026-002
Merck Sharp & Dohme LLC
Phase 1
Completed
7 enrolled
15 charts
NCT05347225
2026-04-30
MK-1026-005
Merck Sharp & Dohme LLC
Phase 1
Active not recruiting
12 enrolled